Research gapMedicine & healthcare

Antimicrobial resistance at the point of care: do rapid tests change prescribing where resistance is highest?

Rapid tests that tell a clinician whether an infection is bacterial, and which antibiotic will work, are being developed by industry and tested by researchers (Nesta, 2024; Smedemark et al., 2022). The trials behind them come mainly from well-resourced health systems, while resistance is most common where diagnostic capacity is weakest (World Health Organization, 2025; Anton-Vazquez et al., 2021).

PhD Research Lab InsightsEditorial team, reviewed by a subject specialist
Posted
5 October 2026
Last checked
5 October 2026
Reading time
10 min
Sources
10
Research proposal support
The gap

We do not yet know whether point-of-care tests that guide antibiotic decisions (biomarker tests such as C-reactive protein, and rapid susceptibility tests) reduce inappropriate prescribing and improve patient outcomes in primary and first-level care in low- and middle-income countries, where resistance is highest (World Health Organization, 2025). The randomised evidence on rapid susceptibility testing comes from specialised centres in high-income countries (Anton-Vazquez et al., 2021).

Population and context gapEmpirical gap (implementation)Evidence gap (patient outcomes)Practical-knowledge gap

What we know

  • In 2021, an estimated 1.14 million deaths were attributable to bacterial antimicrobial resistance and 4.71 million were associated with it (GBD 2021 Antimicrobial Resistance Collaborators, 2024).
  • One in six laboratory-confirmed bacterial infections worldwide in 2023 was resistant to antibiotic treatment, rising to one in three in the WHO South-East Asia and Eastern Mediterranean Regions (World Health Organization, 2025).
  • In primary care trials, C-reactive protein point-of-care testing reduced antibiotic prescribing for acute respiratory infections from 516 to 397 per 1,000 patients (moderate-certainty evidence), without reducing recovery (Smedemark et al., 2022).
  • Combining point-of-care CRP with communication training has been tested as a stewardship strategy in primary care (Cals et al., 2009; Van Hecke et al., 2023).
  • In six randomised trials (1,638 adults with bloodstream infection) in specialised high-income centres, rapid susceptibility testing made little or no difference to mortality (low-certainty evidence) (Anton-Vazquez et al., 2021).
  • A rapid urine test that identifies infection in 15 minutes and the right antibiotic in 45 minutes won the £8 million Longitude Prize on AMR in 2024 (Nesta, 2024).

What we do not know yet

  • Whether CRP and similar biomarker tests change prescribing in low- and middle-income primary care, including pharmacies and community health workers, where antibiotics are often obtained.
  • Whether rapid susceptibility tests, once moved out of specialised hospitals, change the choice of antibiotic and patient outcomes.
  • Which children, older adults and immunocompromised patients benefit, since these groups are under-represented in trials (Smedemark et al., 2022).
  • Cost, supply, quality assurance and workflow requirements for using these tests at scale in first-level care.
  • How test results interact with patient expectations, clinician habits and local treatment guidelines.

Research questions a PhD could ask

  1. Does a point-of-care CRP test, combined with communication support, reduce antibiotic prescribing for acute respiratory infection in primary care in a named low- or middle-income setting, without worse recovery?
  2. When a rapid susceptibility test is used outside specialised hospitals, how often does it change the antibiotic chosen, and how quickly?
  3. What does it cost to deliver a point-of-care test pathway per inappropriate prescription avoided in a given health system?
  4. What facilitators and barriers (supply, training, payment, patient demand) shape whether clinicians act on point-of-care results?
  5. Can routine surveillance data be linked to point-of-care testing to update local treatment guidance?
Methods that could close the gap
ApproachWhy it fits
Pragmatic cluster randomised trialRandomises clinics rather than patients to test a test-and-treat pathway in routine care, the design used in the trials pooled by Smedemark et al. (2022).
Diagnostic impact studyMeasures how often a rapid result changes the antibiotic chosen, the outcome that remained uncertain in Anton-Vazquez et al. (2021).
Economic evaluationModels cost per inappropriate prescription avoided and budget impact for a specific health system.
Implementation researchUses mixed methods and an implementation framework to explain uptake, fidelity and sustainability in first-level care (World Health Organization, 2024a).
Linked surveillance analysisConnects point-of-care results with national data reported to WHO surveillance systems (World Health Organization, 2025).
Gap typeIndustry and research both working on it

The problem

Antibiotics are often prescribed without knowing whether an infection is bacterial or which drug will work, because laboratory results take days or are unavailable. This drives resistance, which now makes common infections harder to treat (World Health Organization, 2025; World Health Organization, 2026).

Why it happens

Standard culture-based diagnosis takes about three days (Nesta, 2024), and the capacity to diagnose bacterial infections is very limited in many low- and middle-income countries (World Health Organization, 2024a). Resistance is more common and worsening where health systems lack that capacity (World Health Organization, 2026).

Where it is felt most

The burden is greatest in South Asia, other parts of Asia and sub-Saharan Africa (GBD 2021 Antimicrobial Resistance Collaborators, 2024), and in primary and community care, where most antibiotics are prescribed and laboratory access is weakest (World Health Organization, 2024a).

How big is the problem

What studies say, and at what level of evidence
LevelWhat it shows
Systematic reviews and meta-analysesCRP point-of-care testing reduced antibiotic prescribing in primary care by about a quarter with moderate certainty (Smedemark et al., 2022); rapid susceptibility testing in high-income hospitals showed little or no effect on mortality, with low certainty (Anton-Vazquez et al., 2021).
Trials or field studiesCluster randomised trials have tested CRP with communication training in primary care (Cals et al., 2009), and expert guidance draws these trials together for practice (Van Hecke et al., 2023).
Observational and surveillance studiesGlobal surveillance shows resistance rising in over 40% of monitored pathogen and antibiotic combinations between 2018 and 2023 (World Health Organization, 2025).
Modelling studiesBurden estimates and forecasts to 2050 show the largest future toll in South Asia (GBD 2021 Antimicrobial Resistance Collaborators, 2024).
Industry and policy reportsA rapid urine susceptibility test won the Longitude Prize in 2024 (Nesta, 2024); WHO lists diagnostic stewardship and access to quality-assured bacteriology among core priorities (World Health Organization, 2024a).
What is missingPragmatic trials and implementation studies of point-of-care pathways in low- and middle-income primary care, with patient outcomes and costs.

Who should take this on

Scholar profile

  • A clinician or pharmacist with access to primary care clinics or community pharmacies in a high-burden country.
  • A microbiologist or laboratory scientist who can run method-comparison studies against reference testing.
  • A health economist interested in the value of diagnostics in constrained health systems.
  • An implementation or health-systems researcher working with ministries of health or stewardship programmes.

Subjects and PhD specialisations

  • Medical microbiology
  • Infectious diseases and antimicrobial stewardship
  • Global or public health
  • Health economics
  • Implementation science
  • Biomedical engineering (diagnostic devices)

Countries where the problem is greatest

Scope for future research

  1. Pragmatic trials of biomarker-guided prescribing in pharmacies and community health services.
  2. Rapid susceptibility tests designed for first-level facilities, evaluated for impact rather than accuracy alone.
  3. Diagnostic pathways for children and older adults with multiple conditions, who are under-represented in trials (Smedemark et al., 2022).
  4. Costing and financing models that make point-of-care testing sustainable in public health systems.
  5. Links between point-of-care results, surveillance and local treatment guidelines (World Health Organization, 2025).

How a doctoral project could address it

  1. Choose the setting and syndrome

    Pick one common syndrome (for example, respiratory or urinary infection) and one level of care in a high-burden country.

  2. Review and map

    Systematically map trials and implementation studies by setting, test and outcome, starting from existing reviews (Smedemark et al., 2022; Anton-Vazquez et al., 2021).

  3. Build partnerships

    Work with clinics, a reference laboratory and, where possible, the national stewardship programme.

  4. Design the study

    Use a pragmatic cluster randomised or stepped-wedge design with prescribing and patient recovery as primary outcomes.

  5. Plan ethics and quality

    Secure ethics approval, consent procedures and quality assurance for the tests.

  6. Add economics and process evaluation

    Measure costs and explain why the pathway did or did not work.

  7. Share results with decision-makers

    Report in formats usable by guideline groups and national action plans (World Health Organization, 2024b).

Why it is worth solving

If point-of-care tests are shown to work in the places where resistance is highest, health systems could cut unnecessary antibiotic use without harming patients, slowing the rise in resistance that already affects one infection in six worldwide (World Health Organization, 2025). Better targeting also means patients with resistant infections reach effective treatment sooner.

For industry, evidence from real first-level care would show which products are worth scaling and at what price. For governments, it would support progress towards the 2030 target to cut deaths associated with AMR by 10% (World Health Organization, 2024b). For science, it would close a clear mismatch between where diagnostics are tested and where they are needed (Anton-Vazquez et al., 2021; GBD 2021 Antimicrobial Resistance Collaborators, 2024).

Why this gap matters now

Antimicrobial resistance is no longer a future threat. More than a million deaths a year are directly attributable to it, and forecasts suggest 39 million more by 2050 (GBD 2021 Antimicrobial Resistance Collaborators, 2024). In 2024, world leaders committed to reduce deaths associated with AMR by 10% by 2030 (World Health Organization, 2024b), and in 2025 WHO reported that one in six laboratory-confirmed infections was resistant (World Health Organization, 2025).

Industry and research are both moving. A rapid urine test that names the right antibiotic in 45 minutes won the Longitude Prize in 2024 (Nesta, 2024), and Cochrane reviews show that biomarker tests can safely reduce prescribing (Smedemark et al., 2022). The missing piece is evidence from the settings with the highest burden, where test, clinic and patient realities differ sharply from those of the trials.

Why the gap persists

Most trials are run where laboratories, funding and research infrastructure already exist. The six randomised trials of rapid susceptibility testing were all in specialised centres in high-income countries (Anton-Vazquez et al., 2021). Meanwhile, WHO notes that capacity to diagnose bacterial infection remains very limited in many low- and middle-income countries (World Health Organization, 2024a).

  • Accuracy studies are easier to run than impact trials, so many tests have evidence of accuracy but not of changed decisions or outcomes.
  • Much antibiotic use happens outside formal clinics, where research access is harder.
  • Supply chains, quality control and payment models for tests are rarely studied alongside clinical effect.

There is also a mismatch of outcomes. Device developers need accuracy data for approval, while health systems need to know whether a test changes what clinicians do, what it costs and whether patients recover as well. WHO has proposed tracking the share of people seeking care in facilities with access to quality-assured bacteriology (World Health Organization, 2024a), but the studies that would show how point-of-care testing contributes to that goal in first-level care are still few.

Is this feasible for a doctorate?

Yes, with a focused scope. A strong thesis might combine a systematic review, a pilot or feasibility cluster trial in a small number of clinics, and an economic and process evaluation. A full definitive trial is usually beyond one doctorate, but a well-run feasibility study is publishable and builds the case for funding.

Practical planning for a doctoral project on point-of-care AMR diagnostics
ConsiderationWhat to plan for
Setting accessAgreements with clinics or pharmacies and local investigators from the start.
EthicsApproval in each country, consent in local languages and plans for patients who test positive.
Test supplyReliable kits, cold chain where needed, and quality assurance against a reference method.
SkillsTrial design, microbiology, health economics and qualitative methods across the supervisory team.
OutcomesPrescribing, recovery and safety, not test accuracy alone.

What to do now

  • Map existing reviews and trials by country income level, setting, test and outcome.
  • Choose one syndrome, one test type and one level of care before drafting research questions.
  • Contact a clinical partner and a reference laboratory early about access and quality assurance.
  • Plan a feasibility study with clear progression criteria rather than a full trial.
Your next step

Could this gap become your thesis?

  1. 1Read the evidence and the open questions
  2. 2Talk to a mentor about fit, data and method
  3. 3Build a defensible proposal
See proposal support

Questions scholars ask

Has CRP testing not already been proven?

It has been shown to reduce prescribing in primary care trials (Smedemark et al., 2022), but most evidence comes from settings that differ from high-burden primary care, so effect and feasibility there remain open questions.

Do I need to develop a new diagnostic device?

No. The gap is mainly about impact and implementation. Evaluating how an existing test performs and changes care in a new setting is a legitimate and valuable doctoral contribution.

Is this only for medical graduates?

No. Microbiologists, pharmacists, public health researchers, health economists and engineers all have a role, ideally within an interdisciplinary supervisory team.

Sources

  1. Anton-Vazquez, V., Hine, P., Krishna, S., Chaplin, M., & Planche, T. (2021). Rapid versus standard antimicrobial susceptibility testing to guide treatment of bloodstream infection. Cochrane Database of Systematic Reviews, CD013235. https://doi.org/10.1002/14651858.CD013235.pub2
  2. Cals, J. W., Butler, C. C., Hopstaken, R. M., Hood, K., & Dinant, G. J. (2009). Effect of point of care testing for C reactive protein and training in communication skills on antibiotic use in lower respiratory tract infections: Cluster randomised trial. BMJ, 338, b1374. https://doi.org/10.1136/bmj.b1374
  3. GBD 2021 Antimicrobial Resistance Collaborators. (2024). Global burden of bacterial antimicrobial resistance 1990–2021: A systematic analysis with forecasts to 2050. The Lancet, 404(10459), 1199–1226. https://doi.org/10.1016/S0140-6736(24)01867-1
  4. Nesta. (2024, June 14). Winners of the £8 million Longitude Prize on AMR announced. Nesta Challenge Works. https://www.nesta.org.uk/blog/winners-of-the-8-million-longitude-prize-on-amr-announced/
  5. Smedemark, S. A., Aabenhus, R., Llor, C., Fournaise, A., Olsen, O., & Jørgensen, K. J. (2022). Biomarkers as point-of-care tests to guide prescription of antibiotics in people with acute respiratory infections in primary care. Cochrane Database of Systematic Reviews, (10), CD010130. https://doi.org/10.1002/14651858.CD010130.pub3
  6. Van Hecke, O., Bjerrum, L., Gentile, I., Hopstaken, R., Melbye, H., Plate, A., Verbakel, J. Y., Llor, C., & Staiano, A. (2023). Guidance on C-reactive protein point-of-care testing and complementary strategies to improve antibiotic prescribing for adults with lower respiratory tract infections in primary care. Frontiers in Medicine, 10, 1166742. https://doi.org/10.3389/fmed.2023.1166742
  7. World Health Organization. (2024a, April 11). Antimicrobial resistance: Accelerating national and global responses (A77/5). Seventy-seventh World Health Assembly. https://apps.who.int/gb/ebwha/pdf_files/WHA77/A77_5-en.pdf
  8. World Health Organization. (2024b, September 26). World leaders commit to decisive action on antimicrobial resistance [News release]. https://www.who.int/news/item/26-09-2024-world-leaders-commit-to-decisive-action-on-antimicrobial-resistance
  9. World Health Organization. (2025, October 13). WHO warns of widespread resistance to common antibiotics worldwide [News release]. https://www.who.int/news/item/13-10-2025-who-warns-of-widespread-resistance-to-common-antibiotics-worldwide
  10. World Health Organization. (2026, July 16). Antimicrobial resistance [Fact sheet]. https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance

How to cite this page

Choose your referencing style, then copy.

PhD Research Lab Insights. (2026, October 5). Antimicrobial resistance at the point of care: do rapid tests change prescribing where resistance is highest?. PhD Research Lab. https://www.phdassistance.com/insights/r-and-d/research-gap/point-of-care-amr-diagnostics/

PhD Research Lab Insights. “Antimicrobial Resistance at the Point of Care: Do Rapid Tests Change Prescribing Where Resistance Is Highest?.” PhD Research Lab, 5 Oct. 2026, www.phdassistance.com/insights/r-and-d/research-gap/point-of-care-amr-diagnostics. Accessed [access date].

PhD Research Lab Insights (2026) Antimicrobial resistance at the point of care: do rapid tests change prescribing where resistance is highest?. PhD Research Lab. Available at: https://www.phdassistance.com/insights/r-and-d/research-gap/point-of-care-amr-diagnostics/ (Accessed: [access date]).

PhD Research Lab Insights. “Antimicrobial Resistance at the Point of Care: Do Rapid Tests Change Prescribing Where Resistance Is Highest?.” PhD Research Lab. October 5, 2026. https://www.phdassistance.com/insights/r-and-d/research-gap/point-of-care-amr-diagnostics.

PhD Research Lab Insights, ‘Antimicrobial Resistance at the Point of Care: Do Rapid Tests Change Prescribing Where Resistance Is Highest?’ (PhD Research Lab, 5 October 2026) <https://www.phdassistance.com/insights/r-and-d/research-gap/point-of-care-amr-diagnostics> accessed [access date].

PhD Research Lab Insights. Antimicrobial resistance at the point of care: do rapid tests change prescribing where resistance is highest? [Internet]. PhD Research Lab; 2026 Oct 5 [cited [access date]]. Available from: https://www.phdassistance.com/insights/r-and-d/research-gap/point-of-care-amr-diagnostics/

PhD Research Lab Insights, “Antimicrobial resistance at the point of care: do rapid tests change prescribing where resistance is highest?,” PhD Research Lab, Oct. 5, 2026. [Online]. Available: https://www.phdassistance.com/insights/r-and-d/research-gap/point-of-care-amr-diagnostics. [Accessed: [access date]].

@online{point_of_care_amr_diagnostics_2026,
  author = {{PhD Research Lab Insights}},
  title = {{Antimicrobial resistance at the point of care: do rapid tests change prescribing where resistance is highest?}},
  organization = {PhD Research Lab},
  date = {2026-10-05},
  url = {https://www.phdassistance.com/insights/r-and-d/research-gap/point-of-care-amr-diagnostics},
  urldate = {[access date]}
}

  • Antimicrobial resistance
  • Point-of-care testing
  • Antibiotic stewardship
  • Global health
  • Diagnostics
Antimicrobial resistance at the point of care: do rapid tests change prescribing where resResearch gap · Medicine & healthcare
Proposal support